Evidence map›Paper›PMID 27702559›Full record

ArticleGastroenterology2016

The Concept of Immune Tolerance in Chronic Hepatitis B Virus Infection Is Alive and Well.

David R Milich

Open access · greenAbstract readEditorialComment
In one paragraph

Article in Gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. [New insights into immunotolerant phase of chronic hepatitis B virus infection].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021
    Article
  12. Article
  13. Review
  14. MHC-E-Restricted CD8Journal of immunology (Baltimore, Md. : 1950) · 2020
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

David R MilichVLP Biotech, Inc, San Diego, California. Electronic address: dmilich@vlp-biotech.com.
VLP Biotech (United States) · US

Funding

A Therapeutic Vaccine for Chronic Hepatitis BR44AI088919 · NIAID · VLP BIOTECH, INC. · PI MILICH, DAVID R. · 2012 to 2020
$4.6M
NIAID NIH HHS R44 AI088919
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hepatitis BHepatitis B AntibodiesHepatitis B, ChronicHepatitis B virusHumansImmune ToleranceHepatitis B Antibodies

Identifiers

PMID27702559
PMCPMC10839812
OpenAlexW2528284989

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.